

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Human epidermal growth factor receptor 2 (HER2) mutations occur most commonly in which region of the receptor?**
 - Extracellular ligand binding domain
 - Transmembrane region
 - Intracellular tyrosine kinase domain (TKD)
 - Carboxyl-terminal tail
- 2. In a cohort of patients with active, untreated CNS metastases, zongertinib demonstrated which intracranial response rate?**
 - Approximately 8%
 - Approximately 25%
 - Approximately 44%
 - Approximately 68%
- 3. Which of the following tyrosine kinase inhibitors has received FDA accelerated approval for patients with HER2 TKD-mutant metastatic non-small cell lung cancer (NSCLC) who have not received prior systemic therapy for advanced disease?**
 - Afatinib
 - Mobocertinib
 - Sevabertinib
 - Zongertinib
- 4. Which of the following statements most accurately compares the gastrointestinal toxicity profiles of zongertinib and sevabertinib?**
 - Zongertinib and sevabertinib are associated with similar rates of diarrhea
 - Zongertinib is associated with lower rates of diarrhea than sevabertinib
 - Zongertinib is associated with higher rates of diarrhea than sevabertinib